Moreover, the concurrent alteration of the FRA1 targets, AXL, CDK6, and FSCN1 correlated with worse prognosis in lung adenocarcinoma, low grade glioma, and clear cell renal cell carcinoma (Supplementary Fig. S5A). Here, AXL is linked to central nervous system cancer.